Target intelligence / Profile preview

Solute carrier family 22 member 17 (SLC22A17)

Target
SLC22A17
Molecular classification
Transporter, Receptor, Membrane protein
01

Overview

Solute carrier family 22 member 17 (SLC22A17), also known as 24p3 receptor, Lipocalin-2 receptor, and several other aliases, is a multi-pass membrane protein classified as both a transporter and a receptor. It binds to the iron-carrying protein lipocalin-2 (LCN2/NGAL), mediating iron uptake or efflux depending on LCN2's iron status. SLC22A17 plays essential roles in iron homeostasis, cell differentiation, apoptosis regulation, and the modulation of inflammatory processes. It is expressed in various tissues and has been implicated in cancers (notably as a biomarker in lung cancer), as well as inflammatory conditions. Currently, there are no approved drugs that specifically target SLC22A17, but its role in disease and physiologic regulation makes it a potential therapeutic target[1][2][9].

Other names
24p3 receptor24p3RBrain-type organic cation transporterLipocalin-2 receptorNeutrophil gelatinase-associated lipocalin receptorNgalRBOCTBOIT
02

Mechanism of action

Regulates iron import/export via binding to the iron-carrying protein lipocalin-2 (LCN2/NGAL), inducing downstream effects on apoptosis and inflammation (potential mechanism for drug action if targeted)[1][2].

03

Biological functions

Iron homeostasis and transportApoptosis regulationCell differentiationInflammation regulation
04

Disease associations

Cancer (e.g., malignant leptomeningeal neoplasm, non-small cell lung cancer prognosis)InflammationPotential roles in metabolic and reproductive processes
05

Safety considerations

Not explicitly detailed; potential challenges may include effects on systemic iron homeostasisrisk of affecting inflammatory responsesoff-target effects due to expression in various tissues[1][2]
06

Biomarkers

SLC22A17 mRNA has been reported as a diagnostic and prognostic biomarker in non-small cell lung cancer[7]

Beyond the preview

Go deeper on Solute carrier family 22 member 17 (SLC22A17).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 22 member 17 (SLC22A17).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call